Skip to main content
Retour
Watch Compare

SUTRO BIOPHARMA, INC.

Qualité des données : 100%
STRO
Nasdaq Manufacturing Chemicals
25,86 €
▼ 0,90 € (-3,36%)
Cap. Boursière: 436,55 M
Prix
26,35 €
Cap. Boursière
436,55 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue grew 13,44% annually over 5 years — strong growth
Negative free cash flow of -177,23 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 51,74%

Croissance

Revenue Growth (5Y)
13,44%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)65,18%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-76,78%
Net Margin-186,45%
Op. Margin-154,53%

Sécurité

Debt / Equity
N/A
Current Ratio2,53
Interest CoverageN/A

Valorisation

PE (TTM)
-2,28
En dessous de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -2,3 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -186,5 -41,5
Rev Growth 5Y % 13,4 1,8
D/E — 0,3

ETFs Holding This Stock

CNCR CNCR
0,76% weight
GCSSX GCSSX
0,07% weight
GCSAX GCSAX
0,07% weight
GCSCX GCSCX
0,07% weight
GCSIX GCSIX
0,07% weight
GDSTX GDSTX
0,07% weight
GCSUX GCSUX
0,07% weight
GMAPX GMAPX
0,07% weight
GDSRX GDSRX
0,07% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 65,18% Revenue Growth (3Y) -18,35%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 13,44% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 102,48 M Net Income (TTM) -191,09 M
ROE N/A ROA -80,97%
Gross Margin N/A Operating Margin -154,53%
Net Margin -186,45% Free Cash Flow (TTM) -177,23 M
ROIC -76,78% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,53
Interest Coverage N/A Asset Turnover 0,43
Working Capital 110,22 M Tangible Book Value -87,27 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,28 Forward P/E N/A
P/B Ratio N/A P/S Ratio 4,26
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -40,60%
Market Cap 436,55 M Enterprise Value 370,62 M
Per Share
EPS (Diluted TTM) -22,49 Revenue / Share 6,19
FCF / Share -10,70 OCF / Share -10,70
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 92,75%
SBC-Adj. FCF -196,13 M Growth Momentum 51,74

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 102,48 M 62,04 M 153,73 M 67,77 M 61,88 M
Net Income -191,09 M -227,46 M -106,79 M -119,20 M -105,54 M
EPS (Diluted) -22,49 -2,96 -1,78 -2,35 —
Gross Profit — — — — —
Operating Income -158,37 M -238,45 M -89,28 M -128,94 M -98,52 M
EBITDA — — — — —
R&D Expenses 166,42 M 252,04 M 180,43 M 137,17 M 104,40 M
SG&A Expenses — — — — —
D&A 7,32 M 7,22 M 6,82 M 5,69 M 4,84 M
Interest Expense — — 1,30 M 2,40 M 2,60 M
Income Tax -93 000,0 2,36 M 18,19 M 2,50 M 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 173,83 M 387,21 M 470,74 M 406,94 M 341,41 M
Total Liabilities 306,28 M 342,61 M 321,09 M 189,90 M 88,84 M
Shareholders' Equity -132,45 M 44,60 M 149,65 M 217,05 M 252,56 M
Total Debt — — 4,06 M 16,27 M 25,11 M
Cash & Equivalents 58,13 M 190,30 M 69,27 M 47,25 M 30,41 M
Current Assets 150,93 M 343,31 M 421,54 M 353,15 M 218,52 M
Current Liabilities 75,13 M 131,89 M 93,75 M 66,55 M 41,74 M